Skip to main content
Premium Trial:

Request an Annual Quote

Acacia Research

Acacia Research announced this week that its subsidiary, Combimatrix Molecular Diagnostics, has launched the third version of its Constitutional Array Genetic Test (CA1000) after completing clinical validation.
The test utilizes the company's Bacterial Artificial Chromosome array, which includes over 200 new, validated probes. Combimatrix acquired the probes through its partnerships with the Center of Applied Genomics in Toronto and the Erasmus University Medical Center in the Netherlands.
The CA1000 improves upon the previous version, the CA850, “by virtue of its increased coverage of genomic loci found in disease ‘hotspots’ further enhancing the test's ability to detect and characterize common genetic disorders,” the company said in a statement.

Filed under

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.